Open AccessAlpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA ‐Mutated HR +/ HER2 – Advanced Breast Cancer
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13662
Subject(s) - letrozole , medicine , breast cancer , cyclin dependent kinase , oncology , aromatase inhibitor , cdk inhibitor , cancer , pharmacology , aromatase , cell cycle
Treatment with alpelisib and letrozole appears to be effective in patients with HR‐positive, HER2‐negative, PIK3CA ‐mutated advanced breast cancer previously treated with a CDK 4/6 inhibitor, according to updated findings from the phase II BYLieve trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom